ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 146

The Arthritis Severity Locus Cia4 Is An Early Regulator of IL-6, IL-1β, and NFκB activators’ Expression in Pristane-Induced Arthritis

Max Brenner1,2, Teresina Laragione1,2 and Percio Gulko1,2, 1Center for Genomics and Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, 2Molecular Medicine, Hosftra North Shore-LIJ School of Medicine, Manhasset, NY

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Animal models, Autoimmunity, cytokines, Gene Expression, genetics and rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Title: Genetics and Genomics of Rheumatic Disease I

Session Type: Abstract Submissions (ACR)

Background/Purpose: Cia4 is a quantitative trait locus on rat chromosome 7 that regulates disease severity and joint damage in three models of rheumatoid arthritis including pristane-induced arthritis (PIA). To identify cellular and molecular processes regulated by Cia4, we studied the expression over 23,000 genes in synovial tissues from MHC identical DA (severe erosive disease) and DA.F344(Cia4) congenics (mild and non-erosive disease) rats.

Methods: Synovial tissues from DA and DA.F344(Cia4) congenics were collected at pre-clinical (day 10 and day 14 post-pristane administration; qPCR) and recent onset (day 18; microarray and qPCR) stages following the induction of PIA and analyzed for gene expression levels.

Results: Il6 levels were 135-fold higher in DA compared with congenics at very early pre-clinical stages (day 10), and remained significantly increased. The Il6 increase preceded the modest increase in Il1b (4.2-fold) suggesting that Il6 could be driving cytokine expression and the early histologic inflammatory infiltration. 187 genes had significantly different expression and included inflammatory mediators expressed in increased levels in DA such Slpi (10.94‑fold) and its receptor Plscr1 (2.31-fold), Cd163 (5.85-fold), Ccl7 (5.17-fold) and Litaf (2.09-fold). Syk or NFκB pathway activating and interacting genes were increased in DA synovial tissues. Fifty-nine genes implicated in cancer-related phenotypes were increased in DA, while genes involved in cell metabolism, transport across membranes and tissue protection such as Acat1, Dgat1, Dhcr7, Slc25a29, and Slc1a1 were increased in DA.F344(Cia4) congenics. 21 genes differentially expressed, or expressed in only one of the two strains were located within the Cia4 interval, and could be the gene accounting for the arthritis effect.

Conclusion: The Cia4 interval contains a new arthritis gene that regulates early Il6, Il1b expression, and other inflammatory mediators central to arthritis, and processes involved in cancer that could be mediating the development of synovial hyperplasia and invasion, and cartilage and bone destruction.


Disclosure:

M. Brenner,
None;

T. Laragione,
None;

P. Gulko,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-arthritis-severity-locus-cia4-is-an-early-regulator-of-il-6-il-1%ce%b2-and-nf%ce%bab-activators-expression-in-pristane-induced-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology